Contact
searchSearch
HMP Global
Login

Ovarian Cancer Specialty Channel

News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer
08/19/2025
Stephanie Holland
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis...
08/19/2025
Oncology
FDA Approval
FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
05/08/2025
Stephanie Holland
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the...
05/08/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer
04/04/2025
Stephanie Holland
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA...
04/04/2025
Oncology
Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
Allison Casey
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
Stephanie Holland
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
Conference Coverage
Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
Allison Casey
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results,...
06/13/2024
Oncology

News

News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer
08/19/2025
Stephanie Holland
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis...
08/19/2025
Oncology
FDA Approval
FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
05/08/2025
Stephanie Holland
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the...
05/08/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer
04/04/2025
Stephanie Holland
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA...
04/04/2025
Oncology
Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
Allison Casey
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
Stephanie Holland
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology

Interactive Features

Quiz
Front-Line Treatment Options for Ovarian Cancer
12/20/2023
12/20/2023
Oncology
Quiz
New and Emerging Targeted Therapies for Relapsing Ovarian Cancer
11/29/2023
11/29/2023
Oncology
Quiz
Maintenance Olaparib Rechallenge for Ovarian Cancer
10/31/2023
10/31/2023
Oncology
Quiz
Sleeping Beauty Mutagenesis in High-Grade Ovarian Cancer
05/16/2023
How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?
How is Sleeping Beauty mutagenesis used to research tumor progression and potentially develop targeted therapies for future treatments for high-grade ovarian cancer?
How is Sleeping Beauty...
05/16/2023
Oncology
Quiz
Quiz: FDA Approves Mirvetuximab Soravtansine
12/15/2022
What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?
What treatment must patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer have received prior to receiving mirvetuximab soravtansine?
What treatment must patients...
12/15/2022
Oncology
Quiz
Quiz: Hyperthermic Intraperitoneal Chemotherapy Agent of Choice
12/02/2022
What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?
What is the most prevalent chemotherapy option when providing HIPEC to patients with ovarian cancer?
What is the most prevalent...
12/02/2022
Oncology
Quiz
Quiz: Pafolacianine With Near-Infrared Imaging for Detecting Folate Receptor-Positive Ovarian Cancer
11/03/2022
A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?
A phase 3 open-label study found that a single infusion of pafolacianine with near-infrared imaging detected the presence of folate-positive ovarian cancer not detected by white light assessment and palpation in what percentage of patients?
A phase 3 open-label study found...
11/03/2022
Oncology
Quiz
Quiz: Promising Novel Therapy in Tough-to-Treat Ovarian Cancer
03/27/2022
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at the SGO 2022 Meeting From report mirvetuximab soravtansine monotherapy demonstrated anti-tumor activity in previously treated patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer.
True or false: Researchers at...
03/27/2022
Oncology
Test Your Knowledge
Quiz: A Common Thread in Rising Endometrial Cases in US Women
05/29/2021
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in the United States, the number of endometrial cancer cases has risen alongside rates of which of the following conditions?
Quiz: Among young adult women in...
05/29/2021
Oncology
Test Your Knowledge
Quiz: Is Intensive Follow-Up of Patients Treated for Endometrial Cancer Beneficial?
05/28/2021
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings presented at the 2021 ASCO Annual Meeting support the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer.
True or False: Study findings...
05/28/2021
Oncology

Recent News

News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer
08/19/2025
Stephanie Holland
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis...
08/19/2025
Oncology
FDA Approval
FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
05/08/2025
Stephanie Holland
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the...
05/08/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer
04/04/2025
Stephanie Holland
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA...
04/04/2025
Oncology
Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
Allison Casey
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
FDA Approval
FDA Approves New Formulation of Thiotepa for Patients With Breast and Ovarian Cancer
07/01/2024
Stephanie Holland
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
Omitting Lymphadenectomy Reduced Post-Operative Morbidity, Did Not Negatively Impact Survival for Patients With Advanced Epithelial Ovarian Cancer
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use